Want to see CATX full AI Analyst Report?
Top Page
Perspective Therapeutics
(CATX)
Select Model
Select Model
Rating:53Neutral
Price Target:
$3.00
▼(-8.81% Downside)
Action:Reiterated
Date:09/09/26
CATX scores in the low-to-mid range primarily due to very weak financial performance today (minimal/volatile revenue, large losses, and heavy cash burn), partially offset by a low-leverage balance sheet. Technicals are broadly neutral with only modest momentum signals, while valuation metrics provide little support due to negative earnings and no dividend. Positive corporate updates around pipeline and manufacturing progress improve the outlook but do not fully offset current operating and cash-flow weakness.
Positive Factors
Clinical pipeline advancement
Progress across three independent clinical-stage programs provides multiple potential paths to registration and future commercial scale. Durable disease control and deepening responses support the possibility that the platform can generate differentiated oncology therapies rather than relying on a single candidate.
Negative Factors
Minimal and declining revenue
The company has not yet demonstrated a stable commercial revenue base, leaving its operating model dependent on successful clinical development and eventual product launches. Continued revenue volatility limits internal funding capacity and makes future financial performance highly sensitive to pipeline outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical pipeline advancement
Progress across three independent clinical-stage programs provides multiple potential paths to registration and future commercial scale. Durable disease control and deepening responses support the possibility that the platform can generate differentiated oncology therapies rather than relying on a single candidate.
Read all positive factors
Perspective Therapeutics (CATX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$357.29M
Dividend YieldN/A
Average Volume (3M)1.06M
Price to Earnings (P/E)―
Beta (1Y)1.44
Revenue Growth-66.88%
EPS Growth-0.42%
CountryUS
Employees165
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.56
Shares Outstanding114,151,665
10 Day Avg. Volume873,590
30 Day Avg. Volume1,055,715
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio-2.13
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.60Price Target Upside282.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-0.97
Revenue Forecast (FY)$352.00K
Perspective Therapeutics Business Overview & Revenue Model
Company Description
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solution...
Perspective Therapeutics Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
72
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 366.00K | 0.00 | 1.45M | 1.43M | 5.42M | 10.79M |
| Gross Profit | -1.53M | 0.00 | -852.00K | 1.43M | 2.37M | 4.62M |
| EBITDA | -116.21M | -100.80M | -64.49M | -39.96M | -8.48M | -7.14M |
| Net Income | -116.43M | -103.12M | -79.28M | -46.51M | -10.76M | -7.27M |
Balance Sheet | ||||||
| Total Assets | 392.02M | 266.97M | 341.10M | 97.89M | 58.09M | 64.44M |
| Cash, Cash Equivalents and Short-Term Investments | 236.88M | 144.74M | 226.92M | 9.24M | 43.76M | 55.89M |
| Total Debt | 3.96M | 3.25M | 4.06M | 2.55M | 524.00K | 524.00K |
| Total Liabilities | 68.16M | 59.94M | 50.43M | 22.71M | 3.45M | 3.16M |
| Stockholders Equity | 323.86M | 207.03M | 290.67M | 75.18M | 54.64M | 61.28M |
Cash Flow | ||||||
| Free Cash Flow | -121.19M | -95.23M | -72.71M | -37.98M | -10.68M | -7.98M |
| Operating Cash Flow | -93.07M | -82.48M | -18.29M | -36.91M | -10.40M | -7.71M |
| Investing Cash Flow | -52.01M | 41.23M | -218.93M | 24.37M | -28.99M | -284.00K |
| Financing Cash Flow | 164.71M | 10.30M | 289.38M | 785.00K | 28.00K | 56.00K |
Perspective Therapeutics Technical Analysis
Negative
3.29
Price Trends
3.14
Negative
3.40
Negative
3.57
Negative
Market Momentum
<0.01
Positive
48.74
Neutral
32.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CATX, the sentiment is Negative. The current price of 3.29 is above the 20-day moving average (MA) of 3.19, above the 50-day MA of 3.14, and below the 200-day MA of 3.57, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 48.74 is Neutral, neither overbought nor oversold. The STOCH value of 32.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CATX.
Perspective Therapeutics Risk Analysis
Perspective Therapeutics disclosed 56 risk factors in its most recent earnings report. Perspective Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Perspective Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $234.25M | 20.08 | 23.38% | ― | 15.28% | 53.24% | |
67 Neutral | $345.84M | 23.30 | 10.30% | ― | 25.21% | 6.14% | |
53 Neutral | $357.29M | -2.00 | -41.56% | ― | -66.88% | -0.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $307.87M | -3.64 | 273.71% | ― | 25.25% | -9.85% | |
46 Neutral | $65.21M | -0.82 | -51.88% | ― | 25.74% | -26.25% | |
42 Neutral | $127.22M | -1.04 | -43.59% | ― | 21.96% | -44.65% |
* Healthcare Sector Average
CATX
Perspective Therapeutics
2.99
-0.24
-7.43%
ELMD
Electromed
27.07
3.42
14.46%
QTRX
Quanterix
2.65
-1.68
-38.80%
VMD
Viemed Healthcare
8.76
2.16
32.73%
NNOX
Nano-X Imaging
0.78
-3.00
-79.37%
TLSI
TriSalus Life Sciences
4.76
0.03
0.63%
Perspective Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Perspective Therapeutics Updates Radiopharmaceutical Oncology Pipeline Outlook
Positive
Sep 8, 2026
On September 8, 2026, Perspective Therapeutics, Inc. updated its corporate presentation to showcase progress across three independent clinical-stage radiopharmaceutical programs, all based on 212Pb and aimed at distinct oncology targets. The mater...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Perspective Therapeutics Reports Q2 Results and Pipeline Progress
Positive
Aug 10, 2026
On August 10, 2026, Perspective Therapeutics reported second-quarter 2026 results and recent business milestones, highlighting continued clinical progress across its 212Pb pipeline and preparations for its first Phase 3 trial. The company detailed...
Business Operations and Strategy
Perspective Therapeutics Advances 212Pb Radiopharmaceutical Oncology Platform
Positive
Aug 3, 2026
On August 3, 2026, Perspective Therapeutics updated its corporate presentation highlighting progress across its 212Pb-based oncology portfolio and integrated radiopharmaceutical platform. The materials emphasize a theranostic strategy, regional pr...
Business Operations and StrategyProduct-Related Announcements
Perspective Therapeutics Highlights Progress in Alpha Radiopharmaceutical Pipeline
Positive
Jul 1, 2026
On July 1, 2026, Perspective Therapeutics, Inc. updated its corporate presentation to highlight progress on its 212Pb-based radiopharmaceutical pipeline and integrated manufacturing strategy. The company emphasized its theranostic approach, target...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.